Bicycle Therapeutics Plc ADR (BCYC) Implied Volatility Current

Tracking BCYC implied volatility helps you identify when options premiums on Bicycle Therapeutics Plc ADR are historically cheap or expensive, and where the best trades are hiding. Bicycle Therapeutics Plc ADR implied volatility reflects the market's expectation of future price movement: when BCYC IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Bicycle Therapeutics Plc ADR's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For BCYC, tracking metrics like BCYC IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on BCYC signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase.

Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where BCYC implied volatility sits today versus where it has been. Our scanner ranks Bicycle Therapeutics Plc ADR implied volatility against its historical range, surfaces extremes in BCYC IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Bicycle Therapeutics Plc ADR IV is rich or cheap — measure it, then act on it.